"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at pazopanib with radiotherapy for people with soft tissue sarcoma (PASART 2)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is for people with soft tissue sarcoma that hasn’t spread and who are going to have treatment with radiotherapy and then surgery.
It is for people going to The Royal Marsden Hospital in London.
More about this trial
Soft tissue sarcoma is a cancer that starts in the supporting tissues of the body (the soft tissue) such as:
- blood vessels
There are different ways to treat soft tissue sarcoma that hasn’t spread. Often people have radiotherapy and then surgery.
Radiotherapy before surgery is called neoadjuvant radiotherapy. This shrinks the cancer so that it’s easier to remove during surgery. This is
Pazopanib (Votrient) is a type of targeted therapy (biological therapy). It blocks a protein called tyrosine kinase that tells cells to divide and grow. Blocking this protein might stop cancer cells from growing.
Pazopanib is already used to help people with soft tissue sarcoma that has come back (recurrent soft tissue sarcoma). Now doctors want to find out if it can also help people with soft tissue sarcoma that hasn’t spread.
The main aims of this trial are to:
- find out how well pazopanib and radiotherapy work as a treatment
- learn about the side effects of treatment
- find out what happens to pazopanib (pharmacokinetics) and the effects it has in the body (pharmacodynamics)
- see if an MRI scan can be used to tell how well treatment works (response to treatment)
Who can enter
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
You may be able to join this trial if all of the following apply.
- You have been diagnosed with soft tissue sarcoma and your doctor thinks that radiotherapy and then surgery is the best treatment for it
- You are able to swallow and absorb tablets
- You have satisfactory blood tests results
- Your heart is working well
- You are at least 18 years old
- You are well enough to carry out your normal activities, apart from heavy physical work (performance status of 0 or 1)
- You are willing to use reliable contraception during treatment and for 6 months afterwards if there is any possibility you or your partner could become pregnant
You cannot join this trial if any of these apply.
- You have soft tissue sarcoma that has come back (recurrent soft tissue sarcoma)
- You have Ewing’s sarcoma, a primitive neuro ectodermal tumour (
PNET), rhabdomyosarcomaor osteosarcoma
- You have had radiotherapy or chemotherapy in the past 2 weeks
- You have had a biological therapy or an experimental treatment in the past month
- You have had another cancer in the past 5 years apart from successfully treated non melanoma skin cancer or an early cancer (
carcinoma in situ)
- You have problems with your
digestive systemsuch as inflammatory bowel disease, colitis, a peptic ulceror any other condition that makes you at risk of having a hole in your bowel or stomach (perforation)
- You have had an operation to remove part of your stomach or bowel (resection)
- You have had a
fistula, a hole (perforation) or an abscessin your tummy in the past 28 day
- You have heart problems such as high blood pressure that is not controlled by medication, congestive heart failure that is causing you symptoms, angina that is not controlled or you have had a heart attack in the past 6 months
- You have had an operation to put a
stentin your heart or a coronary artery bypass graft (CABG) in the last 6 months
- You have a build up of fat in your veins (peripheral vascular disease) that is causing you symptoms or you have had a blood clot in a large vein of your lungs in the past 6 months
- You have a break in a bone (fracture) or a wound that hasn’t healed
- You have had a large operation or injury (trauma) in the past month
- You have had blood in your urine (haematuria) or you have coughed up blood (haemoptysis) is the past 4 weeks
- You are bleeding or have a high risk of it (bleeding diathesis)
- You have an infection that needs treatment that reaches your whole body (systemic treatment)
- You have taken drugs that affect body substances called CYP enzymes in the past 2 weeks
- You have another medical condition or mental health problem that the trial team think could affect you taking part
- You are sensitive to pazopanib or any other similar drug
- You are not able to have an MRI scan for any reason, for example you have metal implants such as a pacemaker, surgical clips, implants, pins, plates, you have a fear of being in closed spaces (claustrophobia) or you are allergic to the dye (
contrast medium) given during the scan
- You are not able to have samples of tissue (
biopsy) taken for any reason
- You are pregnant or breastfeeding
This is an international phase 2 trial. Researchers need about 30 people to take part worldwide and hope that around 20 people going to The Royal Marsden Hospital in London will take part.
You have radiotherapy and take pazopanib tablets. Then you have surgery.
You have a radiotherapy planning scan. The scan helps doctors know how much radiation you need and exactly where you need it. You might also have a radiotherapy mould (or shell) made. This is to keep you still during the treatment.
Then you start radiotherapy. You have it every day, Monday to Friday, with a break at weekends. You have 25 treatments (5 weeks).
Pazopanib comes as tablets that you take every morning, including the weekends.
You start taking pazopanib tablets 1 week before the start of radiotherapy. And you continue taking them until the end of radiotherapy.
You cannot eat for at least 1 hour before the tablets and after you have had the tablets you must wait at least 2 hours before eating.
You have surgery between 6 to 8 weeks after finishing radiotherapy and pazopanib. Your doctor can tell you more about this.
You have some extra blood tests as part of this trial. Researchers want to find out what happens to pazopanib and the effects it has in the body.
You have the extra blood samples before the start of pazopanib and then every week during treatment.
The trial team will ask you to have 2 samples of tissue (biopsies) taken. You have them before the start of treatment and at the start of week 4 of radiotherapy (day 22).
Researchers want to look at the blood vessels (such as veins) that bring oxygen and other substances to the cancer.
You have 3 extra MRI scans as part of this trial. You have them:
- before the start of pazopanib
- on the same day, but before, you start radiotherapy
- on day 22 of radiotherapy
Researchers want to see if the MRI scans can help to tell how well the treatment is working.
The trial team will ask you to keep a diary to record each time you take pazopanib. This helps your doctor see how many doses of treatment you had.
You see a doctor and have some tests before taking part. These tests might include:
During treatment you see the trial doctor every week. You have blood tests and a physical examination.
After you finish radiotherapy and pazopanib, you see the trial doctor after 1 and 2 weeks. Then you have surgery.
After surgery you see the trial doctor every week, for 3 weeks. Then:
- every 3 months for a year
- every 6 months for 4 years
The trial team monitor you during the time you have treatment and you have a phone number to call them if you are worried about anything. The team will tell you about all the possible side effects before you start the trial.
The most common side effects of pazopanib are:
- skin changes (such as redness and soreness)
- feeling or being sick
- changes to the colour of your hair
- high blood pressure
We have more information about pazopanib.
And information about the side effects of:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Aisha Miah (clinical lead for the UK)
The Royal Marsden NHS Foundation Trust
The Netherlands Cancer Institute